AlphaQuest LLC Has $216,000 Stock Holdings in Capricor Therapeutics, Inc. $CAPR

AlphaQuest LLC grew its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 396.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 30,025 shares of the biotechnology company’s stock after buying an additional 23,974 shares during the period. AlphaQuest LLC’s holdings in Capricor Therapeutics were worth $216,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. KLP Kapitalforvaltning AS lifted its holdings in Capricor Therapeutics by 65.2% during the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock worth $108,000 after acquiring an additional 4,300 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Capricor Therapeutics by 6.8% in the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after acquiring an additional 61,701 shares in the last quarter. HBK Sorce Advisory LLC raised its position in shares of Capricor Therapeutics by 33.7% during the third quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company’s stock worth $1,141,000 after purchasing an additional 42,951 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Capricor Therapeutics during the 2nd quarter valued at about $135,000. Finally, Citizens Financial Group Inc. RI grew its position in shares of Capricor Therapeutics by 249.2% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 35,000 shares of the biotechnology company’s stock valued at $348,000 after purchasing an additional 24,977 shares during the period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Down 2.2%

Shares of Capricor Therapeutics stock opened at $24.63 on Wednesday. The stock has a market cap of $1.13 billion, a P/E ratio of -13.68 and a beta of 0.38. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37. The business’s 50 day moving average is $25.94 and its 200-day moving average is $13.43.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). On average, sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. iA Financial set a $48.00 target price on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Oppenheimer raised their price objective on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. HC Wainwright upped their target price on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, December 3rd. Finally, B. Riley Financial reiterated a “buy” rating and set a $50.00 target price (up previously from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.82.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.